CLLS Stock Price | Cellectis SA P/E, Revenue, EPS, & Forecasts

Cellectis SA • CLLS

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Cellectis SA

Ticker

CLLS

Trading on

NASDAQ

ISIN

US15117K1034

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Andre Choulika Ph.D.

Headquarters

8 rue de la Croix Jarry, Paris, undefined, France, 75013

Employees

216

Website

cellectis.com

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Metrics

BasicAdvanced

Market cap

$148M

P/E ratio

EPS

-$0.66

Dividend Yield

0.00%

Beta

3.2

Forward P/E ratio

EBIDTA

$-41M

Ex dividend date

Price & volume

Market cap

$148M

Average daily volume

0.1M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

2.7

Price to book

1.23

Earnings

EPS

-$0.66

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.05

EBITDA

$-41M

Revenues (TTM)

$54.7M

Revenues per share (TTM)

$0.56

Technicals

Beta

3.2

52-week High

$2.43

52-week Low

$1.10

50-day moving average

$1.44

200-day moving average

$1.70

Short ratio

4.38

Short %

0.42%

Management effectiveness

ROE (TTM)

-58.55%

ROA (TTM)

-9.19%

Profit margin

-110.57%

Gross profit margin

$54.7M

Operating margin

-117.89%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

85.10%

Share stats

Outstanding Shares

72.3M

Float

38.9M

Insiders %

3.86%

Institutions %

21.49%

Analyst Insights & forecasts

80% Buy

20% Hold

0% Sell

Based on information from 5 analysts.

Average price target

$5.75

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.28

-$0.30

6.67%

Q2 • 24Beat

-$0.23

-$0.21

-9.52%

Q3 • 24Missed

-$0.16

-$0.21

23.81%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$12.7M

$5.9M

46.57%

Q4 • 24

$10.7M

$-18.1M

-170.14%

Q1 • 25

-16.21%

-406.11%

-465.35%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$384M

$253M

65.84%

Q4 • 24

$364M

$248M

68.08%

Q1 • 25

-5.07%

-1.83%

3.41%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-0M

$-16.7M

$2.9M

$-1.8M

Q4 • 24

$-17.2M

$4.2M

$-4.1M

$-17.6M

Q1 • 25

36,410.64%

-125.35%

-239.86%

879.63%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Cellectis SA share?

Cellectis SA shares are currently traded for undefined per share.

How many shares does Cellectis SA have?

Cellectis SA currently has 72.3M shares.

Does Cellectis SA pay dividends?

No, Cellectis SA doesn't pay dividends.

What is Cellectis SA 52 week high?

Cellectis SA 52 week high is $2.43.

What is Cellectis SA 52 week low?

Cellectis SA 52 week low is $1.10.

What is the 200-day moving average of Cellectis SA?

Cellectis SA 200-day moving average is $1.70.

Who is Cellectis SA CEO?

The CEO of Cellectis SA is Dr. Andre Choulika Ph.D..

How many employees Cellectis SA has?

Cellectis SA has 216 employees.

What is the market cap of Cellectis SA?

The market cap of Cellectis SA is $148M.

What is the P/E of Cellectis SA?

The current P/E of Cellectis SA is null.

What is the EPS of Cellectis SA?

The EPS of Cellectis SA is -$0.66.

What is the PEG Ratio of Cellectis SA?

The PEG Ratio of Cellectis SA is 0.

What do analysts say about Cellectis SA?

According to the analysts Cellectis SA is considered a buy.